Novel medical therapeutics in glioblastomas, including targeted molecular therapies, current and future clinical trials

Neuroimaging Clinics of North America

Volumn 20, Issue 3, 2010, Pages 425-448

  Quant, Eudocia C ^a   Wen, Patrick Y ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Clinical trials; Glioblastoma; Targeted therapy; Tyrosine kinase inhibitors

Indexed keywords

AMG 102; AP 12009; BEVACIZUMAB; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; HEAT SHOCK PROTEIN 90 INHIBITOR; HISTONE DEACETYLASE INHIBITOR; HYDROXYUREA; IMATINIB; IRINOTECAN; MITOGEN ACTIVATED PROTEIN KINASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; NIMOTUZUMAB; PF 299804; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PLATELET DERIVED GROWTH FACTOR; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN KINASE C INHIBITOR; PROTEIN SERINE THREONINE KINASE; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; SCATTER FACTOR; TEMOZOLOMIDE; UNINDEXED DRUG; VASCULOTROPIN; XL 765;

ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER COMBINATION CHEMOTHERAPY; CANCER GENE THERAPY; CANCER GRADING; CANCER RADIOTHERAPY; CANCER STEM CELL; CELL DIFFERENTIATION; CELL GROWTH; CELL MOTILITY; CELL PROLIFERATION; CELL SURVIVAL; CHROMOSOME 10Q; CLINICAL TRIAL; DIARRHEA; DIFFUSION WEIGHTED IMAGING; DNA REPAIR; DRUG BRAIN LEVEL; DRUG DOSE COMPARISON; DRUG ERUPTION; DRUG MEGADOSE; DRUG TARGETING; FARNESYLATION; FATIGUE; GLIOBLASTOMA; HUMAN; LOW DRUG DOSE; MOLECULAR THERAPY; MONOTHERAPY; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; PRIMARY GLIOBLASTOMA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN PROCESSING; REVIEW; SECONDARY GLIOBLASTOMA; SIGNAL TRANSDUCTION; TUMOR VASCULARIZATION; TUMOR VOLUME;

BRAIN NEOPLASMS; CLINICAL TRIALS AS TOPIC; GLIOBLASTOMA; HUMANS; MOLECULAR TARGETED THERAPY; NEOVASCULARIZATION, PATHOLOGIC;

EID: 77955604252     PISSN: 10525149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nic.2010.04.007     Document Type: Review

References (193)

1. Central Brain Tumor Registry of the United States Statistical report: primary brain tumors in the United States, 2000-2004. Available at: Accessed December 1, 2008. http://www.cbtrus.org/reports//2007-2008/2007report.pdf.
2. Stupp R., Mason W.P., van den Bent M.J., et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005, 352(10):987-996.
3. Network CGAR Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008, 455(7216):1061-1068
4. Furnari F.B., Fenton T., Bachoo R.M., et al. Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev 2007, 21(21):2683-2710.
5. Parsons D.W., Jones S., Zhang X., et al. An integrated genomic analysis of human glioblastoma multiforme. Science 2008, 321(5897):1807-1812.
6. Yan H., Parsons D.W., Jin G., et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med 2009, 360(8):765-773.
7. Wen P.Y., Kesari S. Malignant gliomas in adults. N Engl J Med 2008, 359(5):492-507.
8. Kleihues P., Burger P.C., Aldape K.D., et al. Glioblastoma. WHO classification of tumours of the central nervous system 2007, 33-46. International Agency for Research on Cancer, Lyon (France). 4th edition. D.N. Louis, H. Ohgaki, O.D. Wiestler (Eds.).
9. Druker B.J. Perspectives on the development of a molecularly targeted agent. Cancer Cell 2002, 1(1):31-36.
10. Futreal P.A., Kasprzyk A., Birney E., et al. Cancer and genomics. Nature 2001, 409(6822):850-852.
11. Agosti R.M., Leuthold M., Gullick W.J., et al. Expression of the epidermal growth factor receptor in astrocytic tumours is specifically associated with glioblastoma multiforme. Virchows Arch A Pathol Anat Histopathol 1992, 420(4):321-325.
12. Bigner S.H., Humphrey P.A., Wong A.J., et al. Characterization of the epidermal growth factor receptor in human glioma cell lines and xenografts. Cancer Res 1990, 50(24):8017-8022.
13. Humphrey P.A., Wong A.J., Vogelstein B., et al. Amplification and expression of the epidermal growth factor receptor gene in human glioma xenografts. Cancer Res 1988, 48(8):2231-2238.
14. Berens M.E., Rief M.D., Shapiro J.R., et al. Proliferation and motility responses of primary and recurrent gliomas related to changes in epidermal growth factor receptor expression. J Neurooncol 1996, 27(1):11-22.
15. Feldkamp M.M., Lau N., Guha A. Signal transduction pathways and their relevance in human astrocytomas. J Neurooncol 1997, 35(3):223-248.
16. Holland E.C., Hively W.P., DePinho R.A., et al. A constitutively active epidermal growth factor receptor cooperates with disruption of G1 cell-cycle arrest pathways to induce glioma-like lesions in mice. Genes Dev 1998, 12(23):3675-3685.
17. Lund-Johansen M., Bjerkvig R., Humphrey P.A., et al. Effect of epidermal growth factor on glioma cell growth, migration, and invasion in vitro. Cancer Res 1990, 50(18):6039-6044.
18. Sugawa N., Yamamoto K., Ueda S., et al. Function of aberrant EGFR in malignant gliomas. Brain Tumor Pathol 1998, 15(1):53-57.
19. Batra S.K., Castelino-Prabhu S., Wikstrand C.J., et al. Epidermal growth factor ligand-independent, unregulated, cell-transforming potential of a naturally occurring human mutant EGFRvIII gene. Cell Growth Differ 1995, 6(10):1251-1259.
20. Humphrey P.A., Wong A.J., Vogelstein B., et al. Anti-synthetic peptide antibody reacting at the fusion junction of deletion-mutant epidermal growth factor receptors in human glioblastoma. Proc Natl Acad Sci U S A 1990, 87(11):4207-4211.
21. Wong A.J., Ruppert J.M., Bigner S.H., et al. Structural alterations of the epidermal growth factor receptor gene in human gliomas. Proc Natl Acad Sci U S A 1992, 89(7):2965-2969.
22. Chakravarti A, Berkey B, Robins HI, et al. An update of phase II results from RTOG 0211: a phase I/II study of gefitinib with radiotherapy in newly diagnosed glioblastoma. In: Proceedings from the American Society of Clinical Oncology [abstract 1527]. Atlanta (GA), June 2-6, 2006.
23. Brown P.D., Krishnan S., Sarkaria J.N., et al. Phase I/II trial of erlotinib and temozolomide with radiation therapy in the treatment of newly diagnosed glioblastoma multiforme: north central cancer treatment group study N0177. J Clin Oncol 2008, 26(34):5603-5609.
24. Franceschi E., Cavallo G., Lonardi S., et al. Gefitinib in patients with progressive high-grade gliomas: a multicentre phase II study by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). Br J Cancer 2007, 96(7):1047-1051.
25. Rich J.N., Reardon D.A., Peery T., et al. Phase II trial of gefitinib in recurrent glioblastoma. J Clin Oncol 2004, 22(1):133-142.
26. Lieberman FS, Cloughesy T, Fine H, et al. NABTC phase I/II trial of ZD-1839 for recurrent malignant gliomas and unresectable meningiomas. In: Proceedings from the American Society of Clinical Oncology [abstract 1510]. New Orleans (LA), June 5-8, 2004.
27. Cloughesy T, Yung A, Vrendenberg J, et al. Phase II study of erlotinib in recurrent GBM: Molecular predictors of outcome. In: Proceedings from the American Society of Clinical Oncology [abstract 1507]. Orlando (FL), May 13-17, 2005.
28. Vogelbaum M.A., Peereboom D., Stevens G., et al. Phase II study of erlotinib single agent therapy in recurrent glioblastoma multiforme. European Journal of Cancer Supplements 2005, 3(2):135S.
29. Raizer J.J., Abrey L.E., Lassman A.B., et al. A phase II trial of Erlotinib in patients with non-progressive glioblastoma multiforme post radiation therapy, and recurrent malignant gliomas and meningiomas: a North American Brain Tumor Consortium Trial. Neuro Oncol 2010, 12(1):95-103.
30. van den Bent M.J., Brandes A.A., Rampling R., et al. Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034. J Clin Oncol 2009, 27(8):1268-1274.
31. Kuhn J, Robins I, Mehta M, et al. Tumor sequestration of lapatinib (NABTC 04-01). In: Proceedings from the Thirteenth Annual Meeting of the Society for Neuro-Oncology [abstract ET-05]. Las Vegas (NV), November 20-23, 2008.
32. Reardon DA, Groves M, Wen P, et al. A phase II trial of lapatinib and pazopanib for patients with recurrent glioblastoma multiforme (GBM). In: Proceedings from the Twelfth Annual Meeting of the Society for Neuro-Oncology [abstract MA-07]. Dallas (TX), November 15-18, 2007.
33. Thiessen B., Stewart C., Tsao M., et al. A phase I/II trial of GW572016 (lapatinib) in recurrent glioblastoma multiforme: clinical outcomes, pharmacokinetics and molecular correlation. Cancer Chemother Pharmacol 2009, [Epub ahead of print].
34. Stommel J.M., Kimmelman A.C., Ying H., et al. Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science 2007, 318(5848):287-290.
35. Greulich H., Chen T.H., Feng W., et al. Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants. PLoS Med 2005, 2(11):e313.
36. Kobayashi S., Boggon T.J., Dayaram T., et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 2005, 352(8):786-792.
37. Kobayashi S., Ji H., Yuza Y., et al. An alternative inhibitor overcomes resistance caused by a mutation of the epidermal growth factor receptor. Cancer Res 2005, 65(16):7096-7101.
38. Kwak E.L., Sordella R., Bell D.W., et al. Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. Proc Natl Acad Sci U S A 2005, 102(21):7665-7670.
39. Li D., Ambrogio L., Shimamura T., et al. BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene 2008, 27(34):4702-4711.
40. Shimamura T., Ji H., Minami Y., et al. Non-small-cell lung cancer and Ba/F3 transformed cells harboring the ERBB2 G776insV_G/C mutation are sensitive to the dual-specific epidermal growth factor receptor and ERBB2 inhibitor HKI-272. Cancer Res 2006, 66(13):6487-6491.
41. Barber T.D., Vogelstein B., Kinzler K.W., et al. Somatic mutations of EGFR in colorectal cancers and glioblastomas. N Engl J Med 2004, 351(27):2883.
42. Lassman A.B., Rossi M.R., Raizer J.J., et al. Molecular study of malignant gliomas treated with epidermal growth factor receptor inhibitors: tissue analysis from North American Brain Tumor Consortium Trials 01-03 and 00-01. Clin Cancer Res 2005, 11(21):7841-7850.
43. Mellinghoff I.K., Wang M.Y., Vivanco I., et al. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med 2005, 353(19):2012-2024. [erratum appears in N Engl J Med 2006 Feb 23;354(8):884].
44. Ramos T.C., Figueredo J., Catala M., et al. Treatment of high-grade glioma patients with the humanized anti-epidermal growth factor receptor (EGFR) antibody h-R3: report from a phase I/II trial. Cancer Biol Ther 2006, 5(4):375-379.
45. Sampson JH, Archer GE, Bigner DD, et al. Effect of EGFRvIII-targeted vaccine (CDX-110) on immune response and TTP when given with simultaneous standard and continuous temozolomide in patients with GBM. In: Proceedings from the American Society of Clinical Oncology [abstract 2011]. Chicago (IL), May 31-June 3, 2008.
46. Matsumoto K., Nakamura T. Emerging multipotent aspects of hepatocyte growth factor. J Biochem 1996, 119(4):591-600.
47. Koochekpour S., Jeffers M., Rulong S., et al. Met and hepatocyte growth factor/scatter factor expression in human gliomas. Cancer Res 1997, 57(23):5391-5398.
48. Lamszus K., Laterra J., Westphal M., et al. Scatter factor/hepatocyte growth factor (SF/HGF) content and function in human gliomas. Int J Dev Neurosci 1999, 17(5-6):517-530.
49. Moriyama T., Kataoka H., Kawano H., et al. Comparative analysis of expression of hepatocyte growth factor and its receptor, c-met, in gliomas, meningiomas and schwannomas in humans. Cancer Lett 1998, 124(2):149-155.
50. Rosen E.M., Laterra J., Joseph A., et al. Scatter factor expression and regulation in human glial tumors. Int J Cancer 1996, 67(2):248-255.
51. Schmidt N.O., Westphal M., Hagel C., et al. Levels of vascular endothelial growth factor, hepatocyte growth factor/scatter factor and basic fibroblast growth factor in human gliomas and their relation to angiogenesis. Int J Cancer 1999, 84(1):10-18.
52. Reardon DA, Cloughsey TF, Raizer JJ, et al. Phase II study of AMG 102, a fully human neutralizing antibody against hepatocyte growth factor/scatter factor, in patients with recurrent glioblastoma multiforme. In: Proceedings from the American Society of Clinical Oncology [abstract 2051]. Chicago (IL), 2008.
53. Lal B., Goodwin C.R., Sang Y., et al. EGFRvIII and c-Met pathway inhibitors synergize against PTEN-null/EGFRvIII+ glioblastoma xenografts. Mol Cancer Ther 2009, 8(7):1751-1760.
54. George D. Targeting PDGF receptors in cancer-rationales and proof of concept clinical trials. Adv Exp Med Biol 2003, 532:141-151.
55. Di Rocco F., Carroll R.S., Zhang J., et al. Platelet-derived growth factor and its receptor expression in human oligodendrogliomas. Neurosurgery 1998, 42(2):341-346.
56. Hermanson M., Funa K., Hartman M., et al. Platelet-derived growth factor and its receptors in human glioma tissue: expression of messenger RNA and protein suggests the presence of autocrine and paracrine loops. Cancer Res 1992, 52(11):3213-3219.
57. Nister M., Libermann T.A., Betsholtz C., et al. Expression of messenger RNAs for platelet-derived growth factor and transforming growth factor-alpha and their receptors in human malignant glioma cell lines. Cancer Res 1988, 48(14):3910-3918.
58. Chin L.S., Murray S.F., Zitnay K.M., et al. K252a inhibits proliferation of glioma cells by blocking platelet-derived growth factor signal transduction. Clin Cancer Res 1997, 3(5):771-776.
59. Vassbotn F.S., Ostman A., Langeland N., et al. Activated platelet-derived growth factor autocrine pathway drives the transformed phenotype of a human glioblastoma cell line. J Cell Physiol 1994, 158(2):381-389.
60. Cao R., Brakenhielm E., Li X., et al. Angiogenesis stimulated by PDGF-CC, a novel member in the PDGF family, involves activation of PDGFR-alphaalpha and -alphabeta receptors. FASEB J 2002, 16(12):1575-1583.
61. Li X., Eriksson U. Novel PDGF family members: PDGF-C and PDGF-D. Cytokine Growth Factor Rev 2003, 14(2):91-98.
62. Li X., Ponten A., Aase K., et al. PDGF-C is a new protease-activated ligand for the PDGF alpha-receptor. Nat Cell Biol 2000, 2(5):302-309.
63. Kilic T., Alberta J.A., Zdunek P.R., et al. Intracranial inhibition of platelet-derived growth factor-mediated glioblastoma cell growth by an orally active kinase inhibitor of the 2-phenylaminopyrimidine class. Cancer Res 2000, 60(18):5143-5150.
64. Raymond E., Brandes A.A., Dittrich C., et al. Phase II study of imatinib in patients with recurrent gliomas of various histologies: a European Organisation for Research and Treatment of Cancer Brain Tumor Group Study. J Clin Oncol 2008, 26(28):4659-4665.
65. Wen P.Y., Yung W.K., Lamborn K.R., et al. Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08. Clin Cancer Res 2006, 12(16):4899-4907.
66. Dresemann G, Weller M, Bogdahn U, et al. Imatinib plus hydroxyurea versus hydroxyurea monotherapy in progressive glioblastoma-an international multicenter, open-label, randomized phase III study (AMBROSIA-STUDY). In: Proceedings from the Thirteenth Annual Meeting of the Society for Neuro-Oncology [abstract MA-19]. Lake Las Vegas (NV), November 20-23, 2008.
67. Dai H., Marbach P., Lemaire M., et al. Distribution of STI-571 to the brain is limited by P-glycoprotein-mediated efflux. J Pharmacol Exp Ther 2003, 304(3):1085-1092.
68. Hennessy B.T., Smith D.L., Ram P.T., et al. Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov 2005, 4(12):988-1004.
69. Chakravarti A., Zhai G., Suzuki Y., et al. The prognostic significance of phosphatidylinositol 3-kinase pathway activation in human gliomas. J Clin Oncol 2004, 22(10):1926-1933.
70. Opel D., Westhoff M.A., Bender A., et al. Phosphatidylinositol 3-kinase inhibition broadly sensitizes glioblastoma cells to death receptor- and drug-induced apoptosis. Cancer Res 2008, 68(15):6271-6280.
71. Chang S.M., Wen P., Cloughesy T., et al. Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme. Invest New Drugs 2005, 23(4):357-361.
72. Galanis E., Buckner J.C., Maurer M.J., et al. Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study. J Clin Oncol 2005, 23(23):5294-5304.
73. Cloughesy T.F., Yoshimoto K., Nghiemphu P., et al. Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma. PLoS Med 2008, 5(1):e8.
74. Wan X., Harkavy B., Shen N., et al. Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism. Oncogene 2007, 26(13):1932-1940.
75. O'Reilly K.E., Rojo F., She Q.B., et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 2006, 66(3):1500-1508.
76. Sebolt-Leopold J.S., Herrera R. Targeting the mitogen-activated protein kinase cascade to treat cancer. Nat Rev Cancer 2004, 4(12):937-947.
77. Feldkamp M.M., Lau N., Guha A. Growth inhibition of astrocytoma cells by farnesyl transferase inhibitors is mediated by a combination of anti-proliferative, pro-apoptotic and anti-angiogenic effects. Oncogene 1999, 18(52):7514-7526.
78. Glass T.L., Liu T.J., Yung W.K. Inhibition of cell growth in human glioblastoma cell lines by farnesyltransferase inhibitor SCH66336. Neuro Oncol 2000, 2(3):151-158.
79. Kurimoto M., Hirashima Y., Hamada H., et al. In vitro and in vivo growth inhibition of human malignant astrocytoma cells by the farnesyltransferase inhibitor B1620. J Neurooncol 2003, 61(2):103-112.
80. Cloughesy T.F., Wen P.Y., Robins H.I., et al. Phase II trial of tipifarnib in patients with recurrent malignant glioma either receiving or not receiving enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study. J Clin Oncol 2006, 24(22):3651-3656.
81. Lustig R., Mikkelsen T., Lesser G., et al. Phase II preradiation R115777 (tipifarnib) in newly diagnosed GBM with residual enhancing disease. Neuro Oncol 2008, 10(6):1004-1009.
82. Beeram M., Patnaik A., Rowinsky E.K. Raf: a strategic target for therapeutic development against cancer. J Clin Oncol 2005, 23(27):6771-6790.
83. Sharif T.R., Sharif M. Overexpression of protein kinase C epsilon in astroglial brain tumor derived cell lines and primary tumor samples. Int J Oncol 1999, 15(2):237-243.
84. Xiao H., Goldthwait D.A., Mapstone T. The identification of four protein kinase C isoforms in human glioblastoma cell lines: PKC alpha, gamma, epsilon, and zeta. J Neurosurg 1994, 81(5):734-740.
85. Wick W., Puduvalli V.K., Chamberlain M.C., et al. Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma. J Clin Oncol 2010, 28(7):1168-1174.
86. Butowski N.A., Lamborn K., Chang S., et al. Phase I/II study of enzastaurin (ENZ) plus temozolomide (TMZ) and radiation therapy (XRT) in patients with glioblastoma multiforme (GBM) or gliosarcoma (GS). ASCO Meeting Abstracts 2008, 26(Suppl 15):3559.
87. Friedman HS, Desjardins A, Vredenburgh JJ, et al. Phase II trial of erlotinib plus sirolimus for recurrent glioblastoma multiforme (GBM). In: Proceedings from the American Society of Clinical Oncology [abstract 2062]. Chicago (IL), May 30-June 3, 2008.
88. Wen P, Kuhn J, Chang S, et al. Phase I/II study of erlotinib and temsirolimus (CCI-779) for patients with recurrent malignant gliomas (NABTC 04-02). In: Thirteenth Annual Meeting of the Society for Neuro-Oncology. Dallas (TX), November 20-23, 2008.
89. Wen P, Cloughesy T, Kuhn J, et al. Phase I/II study of sorafenib and temsirolimus for patients with recurrent glioblastoma (GBM) (NABTC 05-02). In: Proceedings from the American Society of Clinical Oncology [abstract 2006]. Orlando (FL), May 29-June 2, 2009.
90. Prados M, Gilbert M, Kuhn J, et al. Phase I/II study of sorefenib and erlotinib for patients with recurrent glioblastoma (GBM) (NABTC 05-02). In: Proceedings from the American Society of Clinical Oncology [abstract 2005]. Orlando (FL), May 29-June 2, 2009.
91. Chang S, Kuhn J, Lamborn K, et al. Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas (MG) (NABTC 04-02). In: Proceedings from the American Society of Clinical Oncology [abstract 2004]. Orlando (FL), May 29-June 2, 2009.
92. Jain R.K., di Tomaso E., Duda D.G., et al. Angiogenesis in brain tumours. Nat Rev Neurosci 2007, 8(8):610-622.
93. Chi A.S., Norden A.D., Wen P.Y. Antiangiogenic strategies for treatment of malignant gliomas. Neurotherapeutics 2009, 6(3):513-526.
94. Jin H., Varner J. Integrins: roles in cancer development and as treatment targets. Br J Cancer 2004, 90(3):561-565.
95. Norden A.D., Drappatz J., Wen P.Y. Novel anti-angiogenic therapies for malignant gliomas. Lancet Neurol 2008, 7(12):1152-1160.
96. Millauer B., Shawver L.K., Plate K.H., et al. Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant. Nature 1994, 367(6463):576-579.
97. Friedman H.S., Prados M.D., Wen P.Y., et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 2009, 27:4733-4740.
98. Kreisl T.N., Kim L., Moore K., et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 2009, 27(5):740-745.
99. Vredenburgh J.J., Desjardins A., Herndon J.E., et al. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res 2007, 13(4):1253-1259.
100. Vredenburgh J.J., Desjardins A., Herndon J.E., et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 2007, 25(30):4722-4729.
101. Macdonald D.R., Cascino T.L., Schold S.C., et al. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 1990, 8(7):1277-1280.
102. Nghiemphu P., Green R.M., Pope W.B., et al. Safety of anticoagulation use and bevacizumab in patients with glioma. Neuro Oncol 2008, 10(3):355-360.
103. Norden A.D., Young G.S., Setayesh K., et al. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology 2008, 70(10):779-787.
104. Batchelor TT, Duda DG, di Tomaso E, et al. Phase II study of cediranib, an oral pan-VEGF receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. J Clin Oncol 2010. [Epub ahead of print].
105. Batchelor T.T., Sorensen A.G., di Tomaso E., et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 2007, 11(1):83-95.
106. Jain R.K. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med 2001, 7(9):987-989.
107. Jain R.K. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005, 307(5706):58-62.
108. Holash J., Davis S., Papadopoulos N., et al. VEGF-trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci U S A 2002, 99(17):11393-11398.
109. Wachsberger P.R., Burd R., Cardi C., et al. VEGF trap in combination with radiotherapy improves tumor control in u87 glioblastoma. Int J Radiat Oncol Biol Phys 2007, 67(5):1526-1537.
110. de Groot JF, Wen PY, Lamborn K, et al. Phase II single arm trial of aflibercept in patients with recurrent temozolomide-resistant glioblastoma: NABTC 0601. In: Proceedings from the American Society of Clinical Oncology [abstract 2020]. Chicago (IL), May 30-June 3, 2008.
111. Desjardins A, Barboriak DP, Herndon JE, II, et al. Effect of bevacizumab (BEV) and irinotecan (CPT-11) on dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) in glioblastoma (GBM) patients. In: Proceedings from the American Society of Clinical Oncology [abstract 2026]. Chicago (IL), May 30-June 3, 2008.
112. Norden A.D., Drappatz J., Muzikansky A., et al. An exploratory survival analysis of anti-angiogenic therapy for recurrent malignant glioma. J Neurooncol 2009, 92(2):149-155.
113. Kamoun W.S., Ley C.D., Farrar C.T., et al. Edema control by cediranib, a vascular endothelial growth factor receptor-targeted kinase inhibitor, prolongs survival despite persistent brain tumor growth in mice. J Clin Oncol 2009, 27(15):2542-2552.
114. Lassman AB, Iwamoto FM, Gutin PH, et al. Patterns of relapse and prognosis after bevacizumab (BEV) failure in recurrent glioblastoma (GBM). In: Proceedings from the American Society of Clinical Oncology [abstract 2028]. Chicago (IL), 2008.
115. Narayana A, Raza S, Golfinos JG, et al. Bevacizumab therapy in recurrent high grade glioma: Impact on local control and survival. In: Proceedings from the American Society of Clinical Oncology [abstract 13000]. Chicago (IL), 2008.
116. Zuniga R.M., Torcuator R., Jain R., et al. Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan. J Neurooncol 2009, 91(3):329-336.
117. Kunkel P., Ulbricht U., Bohlen P., et al. Inhibition of glioma angiogenesis and growth in vivo by systemic treatment with a monoclonal antibody against vascular endothelial growth factor receptor-2. Cancer Res 2001, 61(18):6624-6628.
118. Rubenstein J.L., Kim J., Ozawa T., et al. Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption. Neoplasia 2000, 2(4):306-314.
119. Sorensen A.G., Batchelor T.T., Wen P.Y., et al. Response criteria for glioma. Nat Clin Pract Oncol 2008, 5(11):634-644.
120. Wen P.Y., Macdonald D.R., Reardon D.A., et al. Updated response assessment criteria for high-grade gliomas: Response Assessment in Neuro-Oncology (RANO) Working Group. J Clin Oncol 2010, 28(11):1963-1972.
121. van den Bent M.J., Vogelbaum M.A., Wen P.Y., et al. End point assessment in gliomas: novel treatments limit usefulness of classical Macdonald's criteria. J Clin Oncol 2009, 27(18):2905-2908.
122. Gerstner E.R., Sorensen A.G., Jain R.K., et al. Advances in neuroimaging techniques for the evaluation of tumor growth, vascular permeability, and angiogenesis in gliomas. Curr Opin Neurol 2008, 21(6):728-735.
123. Sorensen A.G., Batchelor T.T., Zhang W.T., et al. A " vascular normalization index" as potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients. Cancer Res 2009, 69(13):5296-5300.
124. Chenevert T.L., Stegman L.D., Taylor J.M., et al. Diffusion magnetic resonance imaging: an early surrogate marker of therapeutic efficacy in brain tumors. J Natl Cancer Inst 2000, 92(24):2029-2036.
125. Higano S., Yun X., Kumabe T., et al. Malignant astrocytic tumors: clinical importance of apparent diffusion coefficient in prediction of grade and prognosis. Radiology 2006, 241(3):839-846.
126. Pope W.B., Kim H.J., Huo J., et al. Recurrent glioblastoma multiforme: ADC histogram analysis predicts response to bevacizumab treatment. Radiology 2009, 252(1):182-189.
127. 18F]fluoromisonidazole: a pretherapy study of 37 patients. Int J Radiat Oncol Biol Phys 1996, 36(2):417-428.
128. 18F-FDG. J Nucl Med 2005, 46(6):945-952.
129. Ullrich R., Backes H., Li H., et al. Glioma proliferation as assessed by 3'-fluoro-3'-deoxy-L-thymidine positron emission tomography in patients with newly diagnosed high-grade glioma. Clin Cancer Res 2008, 14(7):2049-2055.
130. Brooks P.C., Clark R.A., Cheresh D.A. Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science 1994, 264(5158):569-571.
131. Brooks P.C., Montgomery A.M., Rosenfeld M., et al. Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell. 1994, 79(7):1157-1164.
132. Friedlander M., Brooks P.C., Shaffer R.W., et al. Definition of two angiogenic pathways by distinct alpha v integrins. Science 1995, 270(5241):1500-1502.
133. Trikha M., Zhou Z., Timar J., et al. Multiple roles for platelet GPIIb/IIIa and alphavbeta3 integrins in tumor growth, angiogenesis, and metastasis. Cancer Res 2002, 62(10):2824-2833.
134. Reardon D.A., Fink K.L., Mikkelsen T., et al. Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme. J Clin Oncol 2008, 26(34):5610-5617.
135. Stupp R, Goldbrunner R, Neyns B, et al. Phase I/IIa trial of cilengitide (EMD121974) and temozolomide with concomitant radiotherapy, followed by temozolomide and cilengitide maintenance therapy in patients (pts) with newly diagnosed glioblastoma (GBM). In: Proceedings from the American Society of Clinical Oncology [abstract 2000]. Chicago (IL), June 2-5, 2007.
136. Richon V.M., Garcia-Vargas J., Hardwick J.S. Development of vorinostat: Current applications and future perspectives for cancer therapy. Cancer Lett 2009, 280(2):201-210.
137. Jones P.A., Baylin S.B. The fundamental role of epigenetic events in cancer. Nat Rev Genet 2002, 3(6):415-428.
138. Galanis E., Jaeckle K.A., Maurer M.J., et al. Phase II trial of vorinostat in recurrent glioblastoma multiforme: a north central cancer treatment group study. J Clin Oncol 2009, 27(12):2052-2058.
139. Adams J., Palombella V.J., Sausville E.A., et al. Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res 1999, 59(11):2615-2622.
140. Pedeboscq S., L'Azou B., Passagne I., et al. Cytotoxic and apoptotic effects of bortezomib and gefitinib compared to alkylating agents on human glioblastoma cells. J Exp Ther Oncol 2008, 7(2):99-111.
141. Laurent N., de Bouard S., Guillamo J.S., et al. Effects of the proteasome inhibitor ritonavir on glioma growth in vitro and in vivo. Mol Cancer Ther 2004, 3(2):129-136.
142. Yin D., Zhou H., Kumagai T., et al. Proteasome inhibitor PS-341 causes cell growth arrest and apoptosis in human glioblastoma multiforme (GBM). Oncogene 2005, 24(3):344-354.
143. Phuphanich S., Supko J., Carson K.A., et al. Phase I trial of bortezomib in adults with recurrent malignant glioma. J Neurooncol 2010, [Epub ahead of print].
144. Kubicek G.J., Werner-Wasik M., Machtay M., et al. Phase I trial using proteasome inhibitor bortezomib and concurrent temozolomide and radiotherapy for central nervous system malignancies. Int J Radiat Oncol Biol Phys 2009, 74(2):433-439.
145. Queitsch C., Sangster T.A., Lindquist S. Hsp90 as a capacitor of phenotypic variation. Nature 2002, 417(6889):618-624.
146. Basso A.D., Solit D.B., Chiosis G., et al. Akt forms an intracellular complex with heat shock protein 90 (Hsp90) and Cdc37 and is destabilized by inhibitors of Hsp90 function. J Biol Chem 2002, 277(42):39858-39866.
147. Lavictoire S.J., Parolin D.A., Klimowicz A.C., et al. Interaction of Hsp90 with the nascent form of the mutant epidermal growth factor receptor EGFRvIII. J Biol Chem 2003, 278(7):5292-5299.
148. An W.G., Schulte T.W., Neckers L.M. The heat shock protein 90 antagonist geldanamycin alters chaperone association with p210bcr-abl and v-src proteins before their degradation by the proteasome. Cell Growth Differ 2000, 11(7):355-360.
149. Miller P., Schnur R.C., Barbacci E., et al. Binding of benzoquinoid ansamycins to p100 correlates with their ability to deplete the erbB2 gene product p185. Biochem Biophys Res Commun 1994, 201(3):1313-1319.
150. Mimnaugh E.G., Chavany C., Neckers L. Polyubiquitination and proteasomal degradation of the p185c-erbB-2 receptor protein-tyrosine kinase induced by geldanamycin. J Biol Chem 1996, 271(37):22796-22801.
151. Schulte T.W., An W.G., Neckers L.M. Geldanamycin-induced destabilization of Raf-1 involves the proteasome. Biochem Biophys Res Commun 1997, 239(3):655-659.
152. Schulte T.W., Blagosklonny M.V., Ingui C., et al. Disruption of the Raf-1-Hsp90 molecular complex results in destabilization of Raf-1 and loss of Raf-1-Ras association. J Biol Chem 1995, 270(41):24585-24588.
153. Whitesell L., Mimnaugh E.G., De Costa B., et al. Inhibition of heat shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation. Proc Natl Acad Sci U S A 1994, 91(18):8324-8328.
154. Kamal A., Thao L., Sensintaffar J., et al. A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature 2003, 425(6956):407-410.
155. Sauvageot C.M., Weatherbee J.L., Kesari S., et al. Efficacy of the HSP90 inhibitor 17-AAG in human glioma cell lines and tumorigenic glioma stem cells. Neuro Oncol 2009, 11(2):109-121.
156. Garcia-Morales P., Carrasco-Garcia E., Ruiz-Rico P., et al. Inhibition of Hsp90 function by ansamycins causes downregulation of cdc2 and cdc25c and G(2)/M arrest in glioblastoma cell lines. Oncogene 2007, 26(51):7185-7193.
157. Xie Q., Thompson R., Hardy K., et al. A highly invasive human glioblastoma pre-clinical model for testing therapeutics. J Transl Med 2008, 6:77.
158. Siegel P.M., Massague J. Cytostatic and apoptotic actions of TGF-beta in homeostasis and cancer. Nat Rev Cancer 2003, 3(11):807-821.
159. Javelaud D., Mauviel A. Crosstalk mechanisms between the mitogen-activated protein kinase pathways and Smad signaling downstream of TGF-beta: implications for carcinogenesis. Oncogene 2005, 24(37):5742-5750.
160. Moustakas A., Heldin C.H. Non-Smad TGF-beta signals. J Cell Sci 2005, 118(Pt 16):3573-3584.
161. Jachimczak P., Hessdorfer B., Fabel-Schulte K., et al. Transforming growth factor-beta-mediated autocrine growth regulation of gliomas as detected with phosphorothioate antisense oligonucleotides. Int J Cancer 1996, 65(3):332-337.
162. Kjellman C., Olofsson S.P., Hansson O., et al. Expression of TGF-beta isoforms, TGF-beta receptors, and SMAD molecules at different stages of human glioma. Int J Cancer 2000, 89(3):251-258.
163. Hau P., Bogdahn U., Olyushin V.E., et al. Results of a phase IIb study in recurrent or refractory glioblastoma patients with the TGF-beta-2 inhibitor AP 12009. J Clin Oncol 2007, 25(18 Suppl):12521. [meeting abstracts].
164. Ma W.W., Adjei A.A. Novel agents on the horizon for cancer therapy. CA Cancer J Clin 2009, 59(2):111-137.
165. Das S., Srikanth M., Kessler J.A. Cancer stem cells and glioma. Nat Clin Pract Neurol 2008, 4(8):427-435.
166. Stiles C.D., Rowitch D.H. Glioma stem cells: a midterm exam. Neuron 2008, 58(6):832-846.
167. Li Z., Wang H., Eyler C.E., et al. Turning cancer stem cells inside out: an exploration of glioma stem cell signaling pathways. J Biol Chem 2009, 284(25):16705-16709.
168. Bao S., Wu Q., McLendon R.E., et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006, 444(7120):756-760.
169. Eyler C.E., Rich J.N. Survival of the fittest: cancer stem cells in therapeutic resistance and angiogenesis. J Clin Oncol 2008, 26(17):2839-2845.
170. Li Z., Bao S., Wu Q., et al. Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells. Cancer Cell 2009, 15(6):501-513.
171. Fulci G., Chiocca E.A. The status of gene therapy for brain tumors. Expert Opin Biol Ther 2007, 7(2):197-208.
172. Aghi M., Rabkin S., Martuza R.L. Effect of chemotherapy-induced DNA repair on oncolytic herpes simplex viral replication. J Natl Cancer Inst 2006, 98(1):38-50.
173. Germano I.M., Binello E. Gene therapy as an adjuvant treatment for malignant gliomas: from bench to bedside. J Neurooncol 2009, 93(1):79-87.
174. Nakamizo A., Marini F., Amano T., et al. Human bone marrow-derived mesenchymal stem cells in the treatment of gliomas. Cancer Res 2005, 65(8):3307-3318.
175. Mamelak A., Rosenfeld S., Bucholz R., et al. Phase I single-dose study of intracavitary-administered iodine-131-TM-601 in adults with recurrent high-grade glioma. J Clin Oncol 2006, 24(22):3644-3650.
176. Ferguson S., Lesniak M.S. Convection enhanced drug delivery of novel therapeutic agents to malignant brain tumors. Curr Drug Deliv 2007, 4(2):169-180.
177. Celtic Pharma terminates TransMID trial KSB311R/CIII/001 February 2, 2007, Celtic Pharma, Available at:, Accessed August 10, 2009. http://www.celticpharma.com/news/pr/transmid_020707.pdf.
178. Sampson J.H., Archer G.E., Bigner D.D., et al. Effect of EGFRvIII-targeted vaccine (CDX-110) on immune response and TTP when given with simultaneous standard and continuous temozolomide in patients with GBM. J Clin Oncol 2008, 26:2011.
179. Nemunaitis J., Jahan T., Ross H., et al. Phase 1/2 trial of autologous tumor mixed with an allogeneic GVAX vaccine in advanced-stage non-small-cell lung cancer. Cancer Gene Ther 2006, 13(6):555-562.
180. Parsa A, Crane C, Butkowski N, et al. Autologous heat shock protein vaccine for recurrent glioma: updated results of a phase I clinical trial. In: Proceedings from the Thirteenth Annual Meeting of the Society for Neuro-Oncology [abstract MA-91]. Lake Las Vegas (NV), November 20-23, 2008.
181. Prados M.D., Chang S.M., Butowski N., et al. Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma. J Clin Oncol 2009, 27(4):579-584.
182. Brandes AA, Stupp R, Hau P, et al. EORTC Study 26041-22041: Phase I/II study on concomitant and adjuvant temozolomide (TMZ) and radiotherapy (RT) with or without PTK787/ZK222584 (PTK/ZK) in newly diagnosed glioblastoma-results of a phase I trial. In: Proceedings from the American Society of Clinical Oncology [abstract 2026]. Chicago (IL), June 2-5, 2007.
183. Rich J.N., Desjardins A., Sathornsumetee S., et al. Phase II study of bevacizumab and etoposide in patients with recurrent malignant glioma. J Clin Oncol 2008, 26(Suppl 15):2022. [meeting abstracts].
184. Hasselbalch B, Lassen U, Soerensen M, et al. A phase II trial with cetuximab, bevacizumab and irinotecan for patients with primary glioblastoma and progression after radiation therapy and temozolomide. In: Proceedings from the Thirteenth Annual Meeting of the Society for Neuro-Oncology [abstract MA-44]. Lake Las Vegas (NV), November 20-23, 2008.
185. Sathornsumetee S, Desjardins A, Vredenburgh JJ, et al. Safety and efficacy of bevacizumab and erlotinib for recurrent glioblastoma patients in a phase II study. In: Proceedings from the Thirteenth Annual Meeting of the Society for Neuro-Oncology [abstract MA-41]. Lake Las Vegas (NV), November 20-23, 2008.
186. Sathornsumetee S, Vredenburgh JJ, Rich JN, et al. Phase II study of bevacizumab and erlotinib in patients with recurrent glioblastoma multiforme. In: Proceedings from the American Society of Clinical Oncology [abstract 13008]. Chicago (IL), May 30-June 3, 2008.
187. de Groot J.F., Gilbert M.R., Aldape K., et al. Phase II study of carboplatin and erlotinib (Tarceva, OSI-774) in patients with recurrent glioblastoma. J Neurooncol 2008, 90(1):89-97.
188. Kreisl T.N., Lassman A.B., Mischel P.S., et al. A pilot study of everolimus and gefitinib in the treatment of recurrent glioblastoma (GBM). J Neurooncol 2009, 92(1):99-105.
189. Phuphanich S, Rudnick J, Chu R, et al. A phase I trial of gefitinib and sirolimus in adults with recurrent glioblastoma multiforme (GBM). In: Proceedings from the American Society of Clinical Oncology [abstract 2088]. Chicago (IL), May 30-June 3, 2008.
190. Prados M.D., Yung W.K., Wen P.Y., et al. Phase-1 trial of gefitinib and temozolomide in patients with malignant glioma: a North American brain tumor consortium study. Cancer Chemother Pharmacol 2008, 61(6):1059-1067.
191. Reardon D, Quinn JA, Rich JN, et al. A phase I trial of imatinib, hydroxyurea and RAD001 for patients with recurrent malignant glioma. In: Proceedings from the American Society of Clinical Oncology [abstract 1580]. Atlanta (GA), June 2-6, 2006.
192. Kirkpatrick JP, Rich JN, Vredenburgh JJ, et al. Final report: phase I trial of imatinib mesylate, hydroxyurea, and vatalanib for patients with recurrent malignant glioma (MG). In: Proceedings from the American Society of Clinical Oncology [abstract 2057]. Chicago (IL), May 30-June 3, 2008.
193. Reardon D.A., Egorin M.J., Desjardins A., et al. Phase I pharmacokinetic study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor vatalanib (PTK787) plus imatinib and hydroxyurea for malignant glioma. Cancer 2009, 115(10):2188-2198.